The infrequent large pelvi-perineal tumors as a surgical dilemma: en bloc resection and long-term results

To assess long-term results of surgical resections of the sporadic extra-large pelvi-perineal soft tissue tumors, a retrospective series of patients referred to the National Cancer Institute 2001–2022 (tertiary care cancer university hospital in Egypt) was designed. Thirteen patients (3 males) averaged age 57 years had large 29 cm (18–38) pelvi-perineal tumors (10 to the paraanal ischiorectal spaces and 3 to the vulva) plus upper intra-abdominal extensions in 9 patients (69%). Symptoms were nonspecific with delayed presentation that averaged 22-month. The entire underwent combined open abdomino-perineal approach to widely en masse resect tumors plus infiltrated organs. No downsizing hormonal treatment was offered preoperative. Main outcome measures were disease free survival, recurrence pattern and salvage. Extensive pelvic and perineal tumor resection is tough and meticulous but straightforward with minor (Clavien-Dindo Classification (CDC) grade I & II) early and delayed morbidity. Resection extends to hysterectomy, vaginectomy and vascular resection. Histopathology plus immunohistochemistry showed 9-aggressive angiomyxoid tumors (AA), 2-fibromatosis and 2-neurofibromas (NF). Margins of resection are all adequate (R0) except for 2 (Resection margin 1 (R1)). After 50-month median follow up, 8/13 total series (61.5%) were surviving free of disease. 4/9 of AA (44%) had local perineal and/or pelvic recurrences (13–37 months) and all were amenable to curative salvage resections; while, 1/2 patients with fibromatosis died of disseminated peritoneal relapses. No systemic metastases are noticed. Extensive tumors meticulous surgery with experienced pelvic dissection and resection could offer alone long term cure even after recurrences with minor morbidity in a good percent. Fertility sparing resection is not oncologically safe because of the frequent uterine and ovarian invasions.

Pelvic neoplasm; Pelvi-perineal tumor; Vulval tumor; Angiomyxoma; Pelvic fibromatosis; Pelvic neurofibroma

[1] Fletcher C, Bridge J, Hogendoorn P, Mertens F. World Health Organization classification of tumours of soft tissue and bone. 4th edn. IARC Press: Lyon. 2013.

[2] Mariani A, Nascimento AG, Webb MJ, Sim FH, Podratz KC. Surgical management of desmoid tumors of the female pelvis. Journal of the American College of Surgeons. 2000; 191: 175–183.

[3] Chen H, Zhao H, Xie Y, Jin M. Clinicopathological features and differential diagnosis of aggressive angiomyxoma of the female pelvis. Medicine. 2017; 96: e6820.

[4] Fetsch JF, Laskin WB, Lefkowitz M, Kindblom L, Meis-Kindblom JM. Aggressive angiomyxoma: a clinicopathologic study of 29 female patients. Cancer. 1996; 78: 79–90.

[5] Zou R, Xu H, Shi Y, Wang J, Wang S, Zhu L. Retrospective analysis of clinicopathological features and prognosis for aggressive angiomyxoma of 27 cases in a tertiary center: a 14-year survey and related literature review. Archives of Gynecology and Obstetrics. 2020; 302: 219–229.

[6] Hsieh F, Chuang K, Wu Y, Lin C. Aggressive angiomyxoma—report of a rare male buttock lesion. Plastic and Reconstructive Surgery—Global Open. 2018; 6: e1879.

[7] Celik SU, Hesimov I, Kutlu B, Erkek AB. Aggressive angiomyxoma: a rare tumor of male pelvic cavity. Acta Médica Portuguesa. 2018; 31: 693–696.

[8] Kumar N, Goyal A, Manchanda S, Sharma R, Kumar A, Bansal VK. Aggressive pelvic angiomyxoma and its mimics: can imaging be the guiding light? The British Journal of Radiology. 2020; 93: 20200255.

[9] Nassar OAH. Primary repair of rectovaginal fistulas complicating pelvic surgery by gracilis myocutaneous flap. Gynecologic Oncology. 2011; 121: 610–614.

[10] Seoud M, Abbas J, Kaspar H, Khalil A, Geara F. Long-term survival following aggressive surgery and radiotherapy for pelvic fibromatosis. International Journal of Gynecological Cancer. 2005; 15: 1112–1114.

[11] D. Mitropoulos W.A. Guidelines on reporting and grading of complications after urologic surgical procedures. European Association of Urology. 2014; 50: 233–40.

[12] Figueiredo G, O’Shea A, Neville GM, Lee SI. Rare mesenchymal tumors of the pelvis: imaging and pathologic correlation. RadioGraphics. 2022; 42: 143–158.

[13] Choi H, Park C, Ji Y. Alternative surgical approaches for aggressive angiomyxoma at different sites in the pelvic cavity. Obstetrics & Gynecology Science. 2015; 58: 525.

[14] Fine BA, Munoz AK, Litz CE, Gershenson DM. Primary medical management of recurrent aggressive angiomyxoma of the vulva with gonadotropin-releasing hormone agonist. Gynecologic Oncology. 2001; 81: 120–122.

[15] Chan IM, Hon E, Ngai SW, Ng Ty, Wong LC. Aggressive angiomyxoma in females: is radical resection the only option? Acta Obstetricia et Gynecologica Scandinavica. 2000; 79: 216–220.

[16] Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, et al. Treatment outcomes and sensitivity to hormone therapy of aggressive angiomyxoma: a multicenter, international, retrospective study. The Oncologist. 2019; 24: e536–e541.